UK Stocks-Factors to watch on Dec 9

Dec 9 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Thursday with futures FFIc1 up 0.16%.

* ASTRAZENECA: The U.S. Food and Drug Administration authorized the use of AstraZeneca's AZN.L antibody cocktail to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.

* COVID-19: Prime Minister Boris Johnson imposed tougher COVID-19 restrictions in England, ordering people to work from home, wear masks in public places and use vaccine passes to slow the spread of the Omicron coronavirus variant.

* SEVERN TRENT: Water company Severn Trent SVT.L has been fined 1.5 million pounds ($2 million) for illegal sewage discharges, Britain's Environment Agency said, after the country launched a major investigation into sewage treatment in November.

* GOLD: Gold prices were flat, as the U.S. dollar and Treasury yields firmed ahead of key inflation data that could provide clues on the Federal Reserve's next policy move.

* METALS: London copper prices slipped as the dollar ticked higher, while signs of easing tightness in nearby supplies of the metal also weighed on the market.

* OIL: Oil prices extended gains on confidence that the Omicron coronavirus variant would not dent global growth, even as some governments stepped up curbs to stop its rapid spread.

* UK's main stock indexes ended flat on Wednesday after hitting session lows as positive headlines on COVID-19 vaccines helped offset concerns about Britain implementing tougher coronavirus measures as early as Thursday.



FY results DS Smith


HY results FirstGroup


HY results Moonpig


HY results Watches of Switzerland


HY results Balfour Beatty


Trading update Rolls-Royce Holdings


Trading update Dr Martens


HY results

* For more on the factors affecting European stocks, please click on:


> Financial Times

> Other business headlines

(Reporting By Amna Karimi in Bengaluru)

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.